These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2125989)

  • 1. Detection of proteins that recognize platinum-modified DNA using gel mobility shift assay.
    Fujiwara Y; Kasahara K; Sugimoto Y; Nishio K; Ohmori T; Saijo N
    Jpn J Cancer Res; 1990 Dec; 81(12):1210-3. PubMed ID: 2125989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-DNA damage recognition proteins in human tumour extracts.
    Bissett D; McLaughlin K; Kelland LR; Brown R
    Br J Cancer; 1993 Apr; 67(4):742-8. PubMed ID: 8471431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands.
    Kido Y; Khokhar AR; al-Baker S; Siddik ZH
    Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of the Escherichia coli UvrAB proteins to the DNA mono- and diadducts of cis-[N-2-amino-N-2-methylamino-2,2,1-bicycloheptane]dichloroplatinum(II ) and cisplatin. Analysis of the factors controlling recognition and proof of monoadduct-mediated UvrB-DNA cross-linking.
    Lambert B; Jestin JL; Bréhin P; Oleykowski C; Yeung AT; Mailliet P; Prétot C; Le Pecq JB; Jacquemin-Sablon A; Chottard JC
    J Biol Chem; 1995 Sep; 270(36):21251-7. PubMed ID: 7673159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding kinetics of tetrachloro-1,2-diaminocyclohexaneplatinum (IV) (tetraplatin) and cis-diamminedichloroplatinum (II) at 37 degrees C with human plasma proteins and with bovine serum albumin. Does aquation precede protein binding?
    LeRoy AF; Thompson WC
    J Natl Cancer Inst; 1989 Mar; 81(6):427-36. PubMed ID: 2918550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients.
    Terheggen PM; Dijkman R; Begg AC; Dubbelman R; Floot BG; Hart AA; den Engelse L
    Cancer Res; 1988 Oct; 48(19):5597-603. PubMed ID: 3046743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognition of platinum-induced DNA damage by nuclear proteins: screening for mechanisms.
    Marples B; Adomat H; Billings PC; Farrell NP; Koch CJ; Skov KA
    Anticancer Drug Des; 1994 Oct; 9(5):389-99. PubMed ID: 7945723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
    Zhai X; Beckmann H; Jantzen HM; Essigmann JM
    Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
    Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
    Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II).
    Toney JH; Donahue BA; Kellett PJ; Bruhn SL; Essigmann JM; Lippard SJ
    Proc Natl Acad Sci U S A; 1989 Nov; 86(21):8328-32. PubMed ID: 2530581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity and cellular accumulation of a new cis-diammineplatinum (II) complex containing procaine in murine L1210 cells sensitive and resistant to cis-diamminedichloroplatinum (II).
    Viale M; Cafaggi S; Parodi B; Esposito M
    Cancer Chemother Pharmacol; 1995; 35(5):371-6. PubMed ID: 7850917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV).
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Sep; 54(17):4691-7. PubMed ID: 8062266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
    Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of binding proteins from ovarian carcinoma and kidney tubule cells that are specific for cisplatin modified DNA.
    Andrews PA; Jones JA
    Cancer Commun; 1991 Mar; 3(3):93-102. PubMed ID: 2001331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
    Hospers GA; Mulder NH; de Jong B; de Ley L; Uges DR; Fichtinger-Schepman AM; Scheper RJ; de Vries EG
    Cancer Res; 1988 Dec; 48(23):6803-7. PubMed ID: 2846161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid reduction of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium.
    Gibbons GR; Wyrick S; Chaney SG
    Cancer Res; 1989 Mar; 49(6):1402-7. PubMed ID: 2924297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
    Yoshida M; Khokhar AR; Siddik ZH
    Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II).
    Sundquist WI; Lippard SJ; Stollar BD
    Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8225-9. PubMed ID: 2446320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells.
    Micetich KC; Barnes D; Erickson LC
    Cancer Res; 1985 Sep; 45(9):4043-7. PubMed ID: 3896476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.